Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas, Inc. (Nasdaq: ARVN) has announced updated safety and efficacy data for ARV-110, a PROTAC protein degrader, during the upcoming 2020 ASCO Annual Meeting. The Phase 1/2 trial targets men with metastatic castration-resistant prostate cancer, showing promising results, including ongoing PSA responses in two patients. The trial has successfully enrolled patients heavily pre-treated with standard therapies such as enzalutamide and abiraterone. Data highlights a sustained safety profile supporting further dose escalation, marking a significant milestone for Arvinas' innovative therapeutic approach.